newsfilter
← Latest News
Business Wire·

PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June